Want to see ILMN full AI Analyst Report?
ILMN Stock Chart & Stats
$194.09
-$4.62(-2.38%)
At close: 4:00 PM EDT
$194.09
-$4.62(-2.38%)
Day’s Range― - ―
52-Week Range$88.00 - $205.93
Previous Close$186.33
Volume1.74M
Average Volume (3M)1.80M
Market Cap
$31.03B
Enterprise Value$28.37K
Total Cash (Recent Filing)$1.17B
Total Debt (Recent Filing)$2.44B
Price to Earnings (P/E)37.9
Beta1.24
Next Earnings
Oct 29, 2026EPS Estimate
1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding151,300,000
10 Day Avg. Volume1,430,344
30 Day Avg. Volume1,800,596
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$189.07Price Target Upside-2.59% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)5.23
Revenue Forecast (FY)$4.57B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables (razor-and-blades)Illumina’s consumables-led model creates durable, recurring revenue once customers adopt its sequencing platforms. Installed-base pull-through aligns customer usage with ongoing reagent purchases, supporting predictable revenue, high gross margins and long-term cash flow visibility tied to sequencing volumes.
High Margins And Strong Cash GenerationSustained high gross and operating margins reflect pricing power in consumables and efficient instrument economics. Robust TTM operating and free cash flow provide the company flexibility for R&D, buybacks and strategic investments, underpinning long-term financial resilience across cycles.
NovaSeq X Placements And Product LeadershipElevated NovaSeq X placements expand the installed base and increase future consumables pull-through, especially in clinical workflows. A larger X footprint shifts volume to higher-throughput systems, supporting sustained consumables demand, higher throughput economics, and long-term revenue growth potential.
Bears Say
Moderate-to-elevated LeverageLeverage near 1x equity limits financial flexibility if headwinds re-emerge. In downturns higher interest or constrained cash flows could force tougher capital-allocation trade-offs, reduce capacity for opportunistic M&A or R&D, and increase vulnerability to working-capital swings tied to instrument cycles.
Multi-year Earnings VolatilityWide swings from losses to strong profits highlight execution and demand cyclicality risks. Such volatility complicates planning, can impair investor confidence, and means margins and cash generation may be less predictable across funding cycles for research customers or during product transitions.
Research Consumables Weakness & Placement ConcentrationDeclines in research consumables and reliance on a few large clinical placements increase revenue concentration and seasonality risk. Slower academic funding or moderation in big customer expansion could quickly reduce consumables demand and make instrument-placement-driven growth lumpy over multiple quarters.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $88.00 and its highest was $205.93 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $31.03B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Oct 29, 2026 which is in 88 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Jul 30, 2026. The company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.226 by $0.084.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.35.
How many shares outstanding does Illumina have?
Illumina has 151,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.31 in its last earnings report, beating expectations of $1.226. Following the earnings report the stock price went up 0.005%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$189.07 (-2.59% Downside)
$189.07 (-2.59% Downside)
Blogger Sentiment
Bullish
ILMN Sentiment 80%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 789.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $146.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 93%
Bearish news 7%
Bearish news 7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.25%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILMN Company Deck
ILMN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: Illumina delivered a quarter with strong top-line beats, materially higher instrument placements (especially NovaSeq X), margin outperformance, raised full-year guidance and strengthened multi-omics and BioInsight momentum (Billion Cell Atlas revenue and partners). Headwinds remain—memory and freight costs, inventory/tax timing impacts, and continued weakness in research consumables and some regions—but management has absorbed costs, secured supply, and raised guidance while reaffirming long-term targets. The positive operational and financial beats and the upgraded outlook outweigh the listed challenges.View all ILMN earnings summariesILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILMN Stock 12 Month Forecast
Average Price Target
$189.07
▼(-2.59% Downside)
Technical Analysis
Ownership Overview
2.13% Insiders
28.21% Mutual Funds
3.28% Other Institutional Investors
42.95% Public Companies and Individual Investors